Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Atossa Genetics Inc (NASDAQ: ATOS).

Full DD Report for ATOS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATOS)

''Robust Economy, Resilient Market''
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2018 / Vista Partners ("Vista") has published August's FREE Macroeconomic & Investment Monthly Newsletter, "Robust Economy, Resilient Market." Vista's monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services,...
Source: ACCESSWIRE IA
Date: August, 23 2018 09:02
"What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?"
SAN FRANCISCO, CA / ACCESSWIRE / August 21, 2018 / The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives on key issues; to create a powerful, global network in order to strengthen the infl...
Source: ACCESSWIRE IA
Date: August, 21 2018 09:05
Atossa Genetics reports Q2 results
Atossa Genetics (NASDAQ: ATOS ): Q2 EPS of -$2.90 vs. -$7.72 in Q217 Cash and cash equivalents of $15.24M Press Release More news on: Atossa Genetics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: August, 13 2018 16:25
Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update
SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced second quarter ended June 30, 2018 financial resu...
Source: GlobeNewswire
Date: August, 13 2018 16:15
The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics"
SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2018 / The Groundwork Forum Podcas t aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives on key issues; to create a powerful, global network in order to strengthen the in...
Source: ACCESSWIRE IA
Date: August, 01 2018 09:05
Atossa Genetics Contracts with Additional Manufacturer of Endoxifen
SEATTLE, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced t...
Source: GlobeNewswire
Date: August, 01 2018 08:00
Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mueller Industries, Inc. (NYSE:MLI), Eros International PLC (NYSE:EROS), ...
Source: GlobeNewswire
Date: July, 31 2018 08:15
Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences - Discovering Underlying Factors of Influence
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetApp, Inc. (NASDAQ:NTAP), eBay Inc. (NASDAQ:EBAY), The Boeing Company (...
Source: GlobeNewswire
Date: July, 30 2018 08:30
Vista Partners Publishes July's Macroeconomic & Investment Newsletter
SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2018 / Vista Partners ("Vista") has published July's FREE Macroeconomic & Investment Monthly Newsletter, "Economy & Market Maintaining Highs." Vista's monthly newsletter contains investment considerations for Banks, Biotech, Cloud Service...
Source: ACCESSWIRE IA
Date: July, 25 2018 09:05
Premarket Gainers as of 9:05 am (07/18/2018)
MTBC +12%  on successfully closes Orion, largest acquisition to date. More news on: Medical Transcription Billing, Energy Fuels Inc, Cellectar Biosciences, Inc., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: July, 18 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-171.221.141.221.12157,698
2018-12-141.221.211.24641.1583,859
2018-12-131.241.181.281.16177,917
2018-12-121.291.2741.29461.23143,338
2018-12-111.281.271.32991.27187,888

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1724,19444,17854.7648Short
2018-12-1417,27127,22163.4473Short
2018-12-135,41848,74311.1154Cover
2018-12-122,81052,3245.3704Cover
2018-12-1122,94249,49046.3568Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATOS.


About Atossa Genetics Inc (NASDAQ: ATOS)

Logo for Atossa Genetics Inc (NASDAQ: ATOS)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $10,183,496 - 05/14/2018
    • Authorized: 75,000,000 - 05/01/2018
    • Issue and Outstanding: 2,651,952 - 05/01/2018

     


    Recent Filings from (NASDAQ: ATOS)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 17 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 16 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 14 2018
    Prospectus filed under Rule 424(b)(4)
    Filing Type: 424B4Filing Source: edgar
    Filing Date: May, 10 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: May, 03 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: April, 27 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 23 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: April, 23 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 17 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 16 2018

     

     


    Daily Technical Chart for (NASDAQ: ATOS)

    Daily Technical Chart for (NASDAQ: ATOS)


    Stay tuned for daily updates and more on (NASDAQ: ATOS)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ATOS)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATOS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATOS and does not buy, sell, or trade any shares of ATOS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/